2021년 신약개발 정부 R&D 투자 포트폴리오 분석

Summary

New drug development is a high-risk, long-term endeavor requiring strategic and efficient investment due to its complexity and high failure rate. South Korea's KISTEP annually analyzes the government R&D investment portfolio in new drug development, categorizing it by development stage, drug type, and target disease, with the aim of enhancing investment strategy and efficiency. The 2021 analysis shows a total government R&D investment of 510.8 billion KRW, with significant focus on infrastructure, candidate substance discovery, and new biologics for infectious diseases, providing crucial data for future strategic planning.

Key Facts

Source Document

https://example-government.gov/policy-document-link